Description
BSE circular detailing the listing of new equity shares of Novelix Pharmaceuticals Limited with lock-in periods ending in March 2026-2027.
Summary
BSE has listed new equity shares of NOVELIX PHARMACEUTICALS LIMITED. The circular provides details of 19 separate allotments totaling equity shares with distinctive numbers ranging from 9950001 to 12935000, with lock-in periods ending between March 2026 and March 2027.
Key Points
- Total of 19 separate equity share allotments listed
- Share allotments range from 10,000 to 15,00,000 shares per allotment
- Distinctive numbers range from 9950001 to 12935000
- Lock-in periods ending primarily on March 30, 2026 and March 31, 2026
- One allotment has extended lock-in period until March 30, 2027
Regulatory Changes
No specific regulatory changes mentioned in this listing circular.
Compliance Requirements
- Listed securities subject to applicable BSE listing regulations
- Lock-in restrictions apply until specified end dates
- Standard compliance requirements for listed pharmaceutical company securities
Important Dates
- Lock-in End Dates:
- March 30, 2026: Majority of allotments (17 out of 19)
- March 31, 2026: Two allotments
- March 30, 2027: One allotment (extended period)
Impact Assessment
Low market impact as this is a standard listing procedure. The listing provides additional liquidity for NOVELIX PHARMACEUTICALS LIMITED shares in the market, though subject to lock-in restrictions until 2026-2027. The staggered lock-in periods may provide gradual market supply over the specified timeframe.
Impact Justification
Standard listing of new securities for a pharmaceutical company with specified lock-in periods